Trump Pharma Price Negotiations
- the Trump administration is increasing pressure on pharmaceutical companies to negotiate drug prices to match those of other countries, where costs are typically much lower.
- An agency spokesperson stated that the Department of Health and Human Services (HHS), under President Trump's direction, is calling on pharmaceutical companies to negotiate pharmaceutical prices transparently.
- The spokesperson added that these companies are "prevent[ing] progress of lowering prices for the American people," though specifics on how they are doing so were not immediately provided.
Trump administration Aims to Lower Drug Prices Through Negotiations
Updated June 13, 2025
the Trump administration is increasing pressure on pharmaceutical companies to negotiate drug prices to match those of other countries, where costs are typically much lower. This initiative seeks to bring fair drug pricing to the United States, a long-standing goal of the administration.
An agency spokesperson stated that the Department of Health and Human Services (HHS), under President Trump’s direction, is calling on pharmaceutical companies to negotiate pharmaceutical prices transparently. The aim is to achieve pricing that is equitable for Americans, similar to agreements these companies already have with other economically comparable nations.
The spokesperson added that these companies are “prevent[ing] progress of lowering prices for the American people,” though specifics on how they are doing so were not immediately provided. This statement follows comments from pharmaceutical executives who said they were awaiting further details regarding which drugs woudl be subject to negotiations and the targeted price points.